SARS-CoV-2 / COVID-19 Assay and Research Solutions
新型コロナウイルス検出における、リアルタイムPCR装置および試薬使用例のご案内
On This Page |
COVID-19 qPCR Assay Development Solutions | COVID-19 Droplet Digital PCR Solutions | Coronavirus Research | News & Media | COVID-19 Resources |
Bio-Rad's products are used in research and clinical laboratories around the world, contributing to advancement of COVID-19 research, SARS-CoV-2 screening assays, and vaccine development. We are committed to providing reliable, sensitive solutions to help you combat this global pandemic.
This page lists our product offerings in these areas. Some products have limited regional availability. If you have a specific question about coronavirus solutions, please contact your local sales office or representative. As we adhere to shelter in place guidelines worldwide, Bio-Rad continues to process orders and offer customer service and technical support.
COVID-19 Assay Development Solutions
For the development and support of SARS-CoV-2 screening assays, we offer a suite of genomic tools including real-time qPCR systems and reagents along with standards for RT-qPCR assay validation. Additionally, we offer droplet digital PCR (ddPCR) products, which provide a powerful complement to the current standard of testing.
COVID-19 Real-Time PCR (qPCR) Assay Development Solutions
Reliance One-Step RT-qPCR Supermix
Robust, reliable one-step RT-qPCR supermix, optimized for sensitive application of up to 5 targets directly from RNA.
Optimized for sensitive amplification of up to 5 targets directly from RNA.
- Ideal for viral & pathogen detection
- Single-tube, 4x ready-to-use supermix
- Multiplex up to 5 targets
- 24-hour room temperature stability for automated workflows
Placing a large order for PCR Reagents?
To place a large order, please contact us for product availability and estimated turnaround time.
SARS-CoV-2 Standards
The EDX SARS-CoV-2 Standard is intended for use as reference material for research testing of the novel coronavirus, allowing laboratories to validate assays. Additionally, the SARS-CoV-2 Standard can be validated for use by the laboratory as an external run control.
-
SARS-CoV-2 Standard
The SARS-CoV-2 Standard contains synthetic RNA transcripts of five SARS-CoV-2 gene targets and human genomic DNA
-
SARS-CoV-2 Negative
The SARS-CoV-2 Negative contains genomic DNA at 75,000 copies/ml formulated in a synthetic matrix
Real-Time PCR Detection Systems
CFX Real-Time PCR Detection Systems are being utilized by multiple testing laboratories for the detection of SARS-CoV-2 (COVID-19). These systems are powerful and flexible instruments, featuring 2–5 color multiplexing, advanced optical technology, and precise temperature control with thermal gradients. CFX Maestro Analysis Software onboard all CFX Instruments provides superior data collection, statistical analysis, and data visualization capabilities.
Real-Time PCR Detection Systems for Research (RUO)
CFX Real-Time PCR (qPCR) Detection Systems
Quickly set up runs and monitor amplification traces in real time on the integrated touch screen, or use CFX Maestro Software to program runs and analyze data remotely.
- Solid-state optics with up to 5-channel multiplexing
- Accurate results with volumes as low as 3 µl
- Internal system qualification and system test software, automated data quality control, and validation tools
- Integrate with LIMS using built-in LIMS file management
- CFX Maestro Software, Security Edition for U.S. FDA 21 CFR Part 11 compliance
Real-Time PCR Detection Systems for In Vitro Diagnostics (IVD)
CFX96 Dx Systems
CFX96 Dx Systems are CE-IVD marked in compliance with the E.U. diagnostic medical device manufacturing standards for use in human in vitro diagnostics.*
- Up to 5-target multiplexing with Reliance One-Step Multiplex Supermix, reduces sample and reagent use
- Quickly and accurately analyze and validate data with CFX Manager Dx Software
- Reaction volumes: CFX Dx, 10–50 µl; CFX Dx Deep Well, 10–125 µl
- Microtube formats: 96-well plates, 8-well strips
COVID-19 Droplet Digital PCR Solutions
How to Order 2019-nCOV CDC ddPCR Assay
Click the button below or go to
Bio-Rad.com/COVID-19-ddPCR
Log in to your Bio-Rad.com account; if you do not have an account, choose Register Today
Select Add to My Designs
Click Add Assay to Cart
Add to cart any reagents and consumables needed and check out
COVID-19 Droplet Digital PCR (ddPCR) Assay
Bio-Rad has developed a COVID-19 ddPCR assay designed to be a powerful nucleic acid tool in the battle against COVID-19, with sensitivity and precision beyond that of qPCR assays.
The 2019-nCoV CDC ddPCR Triplex Probe Assay is a quantitative assay optimized for use on our QX200 and QXDx Droplet Digital PCR Systems using the 1-Step RT-ddPCR Advanced Kit for Probes and SARS-CoV-2 positive and negative standards. The 2019-nCoV CDC ddPCR Assay is currently for research use only (EUA pending for diagnostic use).
- High sensitivity and precision in low viral abundance samples
- Resistant to inhibition often seen in RT-PCR testing
- Single-well test – 3 sequences aligned to CDC markers: SARS-CoV-2 N1 and N2 genes, human RPP30 gene
- Available in 200 reactions (1,000 reactions coming soon)
Droplet Digital PCR Systems
Bio-Rad’s Droplet Digital PCR Systems provide ultrasensitive and absolute nucleic acid quantification. Droplet Digital PCR is particularly useful for low-abundance targets, targets in complex backgrounds, or monitoring subtle changes in target levels that cannot be detected with real-time PCR.
-
QX200 AutoDG Droplet Digital PCR System for Research (RUO)
- Simplifies ddPCR workflow and ensures consistency
- Generates droplets for 96 ddPCR reactions in 45 minutes
- One AutoDG Instrument can supply 4–5 droplet readers
- HEPA-filtered enclosure reduces contamination risk
-
QXDx AutoDG ddPCR System for In-Vitro Diagnostics (IVD)
- First FDA-cleared ddPCR system for use with QXDx BCR-ABL %IS Kit
- Ultra-low quantification without standard curves
- Droplet partitioning reduces amplification bias
- Automated droplet generator, 96-reaction throughput
Droplet Digital PCR System Consumables
Purchase droplet generation oil, cartridges, gaskets, plates & seals, and pipette tips, and more, designed for Droplet Digital PCR Systems.
Buy ddPCR Consumables »-
Droplet Digital PCR System Supermix
One-Step RT-ddPCR Advanced Kit for Probes for use with the COVID-19 ddPCR Assay.
Buy ddPCR Supermix »
Coronavirus Research
For the characterization of genomic profiles and changes in cytokines and chemokine production associated with the disease state of coronavirus, we offer Immunoassay tools and real-time PCR assay panels.
Multiplex Immunoassay Panels for Coronavirus Research
To characterize the effect of coronavirus on the production of cytokines and chemokines in disease states, these analytes can be quantitated from serum or other clinical samples using the Bio-Plex Multiplex Immunoassay System, as described in a recent publication in Lancet (Huang C et al. 2020), that describes the clinical features of patients infected with COVID-19/2019-nCoV.
Bio-Plex Pro Human Cytokine, Chemokine, and Growth Factor Assays
Based on Luminex beads, this panel enables you to detect the most researched and biologically relevant human cytokines in a single well.
- Quantitate endogenous and diseased/treated conditions in one assay
- Detect and quantify up to 48 cytokines in one well
- Requires only a 12.5 µl sample
Other Bio-Plex Immunoassays
Assays for over 450 biologically relevant targets are available as ready-to-use premixed multiplex panels and singleplex sets, or in custom-mixed panels. Bio-Plex beads and coupling kit enable you to develop new assays for novel targets.
- Bio-Plex Pro Cytokine, Chemokine, and Growth Factor Assays
- Bio-Plex Multiplex Assays
- Bio-Plex Beads and Coupling Kit
Real-Time PCR Assay Panel for Coronavirus Disease Research
Study differential gene expression in response to coronavirus infection using our disease state qPCR assay panels.
- Bench-tested, guaranteed-to-perform assays
- Obtain gene expression profile of a whole pathway in one experiment
- Assay panels for human, mouse, and rat genes
Antibody Solutions for Coronavirus Research
Bio-Rad Antibodies provide complete solutions for all your antibody needs, with a large catalog of highly cited antibodies, and the ability to provide custom monoclonal generation in just 8 weeks.
Antibodies for Immune Cell Characterization in COVID-19 Infection
Antibodies to profile immune response to COVID-19 infection and monitor virus-induced inflammation. Choose from thousands of antibodies against targets including:
- Innate immune response to viral infection: pattern recognition receptors
and toll-like receptors - Targeted adaptive immune response against the virus: T cell and B cell markers
- Inflammatory response: cytokines and chemokines
Rapid Custom Antibody Generation with HuCAL® Technology
Get highly specialized antibodies for coronavirus research, diagnostic testing, plus vaccine and therapeutic development
- Fab antibodies against your target antigens in as little as 8 weeks
- Conversion to fully human IgG and IgM serological control antibodies
- Anti-idiotypic antibodies against your biologic drug for bioanalytical assays
Flow Cytometry Analysis for COVID-19 Research and Vaccine Development
Profile virus- and vaccine-induced immune responses with the ZE5 Cell Analyzer.
- High-parametric antiviral immunophenotyping
- High-throughput screening of therapeutic drug candidates
- Rapid discovery of neutralizing antibodies
- Evaluation of T cell-stimulating viral epitopes for vaccine candidates
- Detection of pro-inflammatory cytokines and cytokine receptors
News & Media
Media Contacts
Tina Cuccia
Corporate Communications Manager
Phone: 510-741-6063
tina_cuccia@bio-rad.com
COVID-19 Resources
FEATURED WEBINARCoronavirus Outbreak: The Singapore Story
The Development of a Locally Made Diagnostic Kit to Combat the COVID-19 Pandemic
Learn how Bio-Rad helped the Singapore Agency for Science, Technology, and Research (A*STAR) develop their SARS-CoV-2 test kit for use in hospitals across Singapore.
2019-20 Coronavirus Pandemic (COVID-19; 2019-nCoV)
The novel coronavirus identified as the causative agent of pneumonia cases first detected in Wuhan City, China in December, 2019, was officially designated as SARS-CoV-2. On March 11, 2020, WHO declared COVID-19 a global pandemic. For the latest information on the Novel Coronavirus COVID-19 / 2019-nCoV pandemic, visit the World Health Organization website:
WHO.int > Emergencies > Diseases > Coronavirus disease 2019
The US Centers for Disease Control and Prevention provides valuable information for US and global citizens. See the CDC website for the 2019 Novel Coronavirus Situation Summary, guidance for travelers, information for healthcare and public health professionals, guidance for laboratory professionals, background information, and the latest news:
CDC.gov > 2019 Novel Coronavirus
Although there are no clinical diagnostics for coronavirus 2019-nCoV currently approved by the US Food & Drug Administration (FDA), on February 4th, 2020, the FDA issued an Emergency Use Authorization to temporarily expand the use of RT-PCR assays for the identification of 2019-nCoV. For updates, see the US Food & Drug Administration website:
FDA.gov > Medical Countermeasures Initiative (MCMi) > Novel Coronavirus (2019-nCoV)
FDA.gov > Medical Countermeasures Initiative (MCMi) > Emergency Use Authorization
* Legal Notice:
The CFX96 Dx System is intended for use in the fields of research and human in vitro diagnostics. The system is CE-IVD marked in compliance with the European Union diagnostic medical device manufacturing standards.
Europe: For in vitro diagnostic use. The CFX96 Dx System and CFX96 Deep Well Dx System meet the requirements of the In Vitro Diagnostic Medical Devices Directive (98/79/EC). The CE IVD–registered CFX96 Dx and CFX96 Deep Well Dx Systems are for distribution and use in specific European countries only (Austria, Belgium, Bulgaria, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Poland, Portugal, Slovenia, Spain, and Sweden).
USA: The CFX96 Dx and CFX96 Deep Well Dx Systems are not available for sale in the U.S.A.
China: The CFX96 Deep Well Dx System is registered for In Vitro Diagnostic use.
Worldwide: The CFX96 Dx and CFX96 Deep Well Dx Systems are registered for In Vitro Diagnostic use in the following countries: Argentina, Australia, Belarus, Bolivia, Brazil, Brunei, Chile, Colombia, Costa Rica, Dominican Republic, Egypt, Hong Kong, India, Laos, Morocco, New Zealand, Norway, Pakistan, Philippines, Qatar, S. Korea, Saudi Arabia, Singapore, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Kingdom, Ukraine, Vietnam, and Yemen.
These products and/or their use are covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. Purchase of a product includes a limited, non-transferable right under such intellectual property for use of the product for internal research and diagnostic purposes only. No rights are granted for use of a product for commercial applications of any kind, including but not limited to manufacturing, quality control, or commercial services, such as contract services or fee for services. Information concerning a license for such uses can be obtained from Bio-Rad Laboratories. It is the responsibility of the purchaser/end user to acquire any additional intellectual property rights that may be required.
Kits and reagents are sold for research use only. Not for use in diagnostic procedures.
Scroll